<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Apellis Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/apellis-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Apellis Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/apellis-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835471a78dffbe2df0e3432.webp</url>
      <title>Apellis Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/biogen-to-acquire-apellis-enhancing-the-companys-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/biogen-to-acquire-apellis-enhancing-the-companys-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare</description>
    </item>
    <item>
      <title>Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-mikael-dolsten-md-phd-to-join-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-mikael-dolsten-md-phd-to-join-board-of-directors</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Tue, 24 Feb 2026 12:05:00 GMT</pubDate>
      <description>Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025;</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast</description>
    </item>
    <item>
      <title>Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-eight-oral-presentations-at-the-49th-macula-society-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-eight-oral-presentations-at-the-49th-macula-society-annual-meeting</guid>
      <pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
      <description>Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection)</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-host-conference-call-120000851</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-host-conference-call-120000851</guid>
      <pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and</description>
    </item>
    <item>
      <title>Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-highlights-commercial-execution-and-strategic-priorities-44th-annual-jp</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-highlights-commercial-execution-and-strategic-priorities-44th-annual-jp</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year;</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2026-01</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2026-01</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44th</description>
    </item>
    <item>
      <title>Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/sobi-receives-positive-chmp-opinion-for-aspavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-2</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/sobi-receives-positive-chmp-opinion-for-aspavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-2</guid>
      <pubDate>Fri, 12 Dec 2025 13:12:00 GMT</pubDate>
      <description>Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).</description>
    </item>
    <item>
      <title>The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/new-england-journal-medicine-publishes-positive-phase-3-valiant-results-empavelir</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/new-england-journal-medicine-publishes-positive-phase-3-valiant-results-empavelir</guid>
      <pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
      <description>Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-participate-upcoming-investor-conferences-2025-11-25</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-participate-upcoming-investor-conferences-2025-11-25</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast</description>
    </item>
    <item>
      <title>Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-5-year-gale-data-showing-syfovrer-pegcetacoplan-injection-delayed</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-5-year-gale-data-showing-syfovrer-pegcetacoplan-injection-delayed</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-present-stifel-2025-healthcare-conference-2025-11-05</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-present-stifel-2025-healthcare-conference-2025-11-05</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-10-30</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-10-30</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan)</description>
    </item>
    <item>
      <title>New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/new-one-year-data-reinforcing-robust-and-sustained-efficacy-empavelir-pegcetacoplan</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/new-one-year-data-reinforcing-robust-and-sustained-efficacy-empavelir-pegcetacoplan</guid>
      <pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
      <description>Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-host-conference-call-october-30-2025-discuss-third-quarter</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-host-conference-call-october-30-2025-discuss-third-quarter</guid>
      <pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
      <description>Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-reports-second-quarter-2025-financial-results-2025-07-31</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-reports-second-quarter-2025-financial-results-2025-07-31</guid>
      <pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
      <description>Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty</description>
    </item>
    <item>
      <title>FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/fda-approves-apellis-empavelir-pegcetacoplan-first-c3g-and-primary-ic-mpgn-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/fda-approves-apellis-empavelir-pegcetacoplan-first-c3g-and-primary-ic-mpgn-treatment</guid>
      <pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
      <description>Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3</description>
    </item>
    <item>
      <title>Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-host-conference-call-july-31-2025-discuss-second-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-pharmaceuticals-host-conference-call-july-31-2025-discuss-second-quarter-2025</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call</description>
    </item>
    <item>
      <title>Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting</title>
      <link>https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-five-abstracts-accepted-oral-presentation-american-society-retina</link>
      <guid isPermaLink="true">https://6ix.com/company/apellis-pharmaceuticals-inc/news/apellis-announces-five-abstracts-accepted-oral-presentation-american-society-retina</guid>
      <pubDate>Tue, 15 Jul 2025 04:00:00 GMT</pubDate>
      <description>Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension</description>
    </item>
  </channel>
</rss>